StockNews.AI
UNCY
StockNews.AI
90 days

Unicycive Therapeutics Announces Time Change for 2025 Annual Meeting of Stockholders

1. Unicycive's Annual Meeting scheduled for June 9, 2025, at 7:00 a.m. PDT. 2. Stockholders can find meeting details via Unicycive's dedicated link. 3. Unicycive is developing oxylanthanum carbonate for kidney disease treatment. 4. UNI-494 aims to address acute kidney injury, with ODD from the FDA. 5. Oxylanthanum carbonate is under FDA review for hyperphosphatemia treatment.

4m saved
Insight
Article

FAQ

Why Bullish?

Positive developments around FDA reviews can enhance investor confidence and valuation, similar to other biotech companies experiencing stock price surges post-approval announcements.

How important is it?

The announcement involves FDA review for key products, significantly impacting market expectations and stock prices.

Why Long Term?

The ongoing FDA review could lead to long-term growth if products are approved, paralleling historical instances with other biotech firms that saw sustained price increases.

Related Companies

KRTXNTRA
May 21, 2025 07:00 ET  | Source: Unicycive Therapeutics, Inc. LOS ALTOS, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ: UNCY) (“Unicycive” or the “Company”), a clinical stage biotechnology company developing therapies for patients with kidney disease, today announced a change in the time of the 2025 Annual Meeting of Stockholders (the “Annual Meeting”). The previously announced date of the meeting (June 9, 2025) and location of the meeting (4300 El Camino Real, Suite 210, Los Altos, CA 94022) will not change, but the meeting will be held at 7:00 a.m., Pacific Daylight Time, on that date. Stockholders of record as of the close of business on April 30, 2025, the record date, can find additional details regarding participation in the Annual Meeting at https://annualgeneralmeetings.com/uncy2025. About Unicycive Therapeutics Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead investigational treatment is oxylanthanum carbonate, a novel phosphate binding agent currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Unicycive’s second investigational treatment UNI-494 is intended for the treatment of conditions related to acute kidney injury. It has been granted orphan drug designation (ODD) by the FDA for the prevention of Delayed Graft Function (DGF) in kidney transplant patients and has completed a Phase 1 dose-ranging safety study in healthy volunteers. For more information about Unicycive, visit Unicycive.com and follow us on LinkedIn and X. Investor Contacts: Kevin GardnerLifeSci Advisorskgardner@lifesciadvisors.com Media Contact: Rachel Visi Real Chemistryredery@realchemistry.com SOURCE: Unicycive Therapeutics, Inc.

Related News